Dyno Therapeutics announced a collaboration with NVIDIA to leverage Dyno’s field-leading artificial intelligence and in vivo experimentation capabilities, along with the built-to-scale NVIDIA BioNeMo AI-powered drug design platform, to help advance biological sequence design.
